生物技术通报 ›› 2022, Vol. 38 ›› Issue (9): 96-105.doi: 10.13560/j.cnki.biotech.bull.1985.2022-0089

• 细菌耐药性专题(专题主编: 刘雅红 教授 孙坚 教授) • 上一篇    下一篇

非抗生素类活性物质抗幽门螺杆菌研究进展

刘晓黎(), 童真艺, 赵亮, 尹丽, 刘晨光()   

  1. 中国海洋大学海洋生命学院,青岛 266000
  • 收稿日期:2022-01-19 出版日期:2022-09-26 发布日期:2022-10-11
  • 作者简介:刘晓黎,男,硕士研究生,研究方向:生物表面活性剂在抗菌及抗生物膜方面应用;E-mail: 723140523@qq.com
  • 基金资助:
    山东省自然科学基金(ZR2018MC010)

Research Progress in Non-antibiotic Active Substances Against Helicobacter pylori

LIU Xiao-li(), TONG Zhen-yi, ZHAO Liang, YIN Li, LIU Chen-guang()   

  1. College of Marine Life Science,Ocean University of China,Qingdao 266000
  • Received:2022-01-19 Published:2022-09-26 Online:2022-10-11

摘要:

幽门螺杆菌感染与多种胃部相关疾病(如胃溃疡、胃癌等)密切相关,是一种严重威胁人类健康的全球性流行病。过去临床上主要通过三联或四联疗法治疗幽门螺杆菌感染,然而由于抗生素的长期使用,幽门螺杆菌不断产生耐药性,导致临床治愈率逐年下降。针对这一问题,近年来非抗生素类抗菌活性物质由于不易诱导耐药性而逐渐受研究者更多关注。本文综述了非抗生素类活性物质(包括植物天然产物、糖脂、多不饱和脂肪酸、抗菌肽、尿素代谢抑制剂和益生菌)在抗幽门螺杆菌感染领域的研究概况和进展,重点介绍了不同活性物质的抗菌机制(如破坏细胞膜、抗生物膜、抑制幽门螺杆菌脲酶、竞争性抑制细菌粘附和分泌细菌素等)和对宿主机体的影响(如抗炎、抑制凋亡、促进黏膜和溃疡的修复及调节消化道菌群等),同时还比较了它们在临床上应用途径的差异。最后,提出了该领域未来需要解决的关键问题,以期为这类物质开发为药物并用于临床提供理论依据与参考。

关键词: 幽门螺杆菌, 耐药性, 非抗生素活性物质, 天然产物, 抗菌活性

Abstract:

Helicobacter pylori infection is closely related to multiple gastric diseases,it is global epidemics threatening human health. In past few decades,the main treatment of H. pylori infection were combination of a variety of antibiotics. However,due to long-term abuse of antibiotics and nature defects of threatment,H. pylori obtained resistance to clinical drugs,leading to the clinical cure rate declined steadly. In response to this issue,non-antibiotics antibacterial active substances gained more attention from researchers in recent years because it induce less drug resistance. This review summarizes the updated status and progress of non-antibiotic substances(includes natural product from plant,glycolipids,polyunsaturated fatty acids,antimicrobial peptide,urease metabolism inhibitor and probiotics)against H. pylori infection,while focusing on the antibacterial mechanism(such as lysing membrane,anti-biofilm,inhibiting H. pylori urease,competitively inhibiting adhesion and secreting bacteriocin)and effect of host body(such as anti-inflammation,inhibiting cell apoptosis,promoting the repair of mucosa and uclers,and regulating digestive canal flora). At the same time,the differences of their clinical application approaches of different active substances. Finally,the current key challenges are also included,aiming to provides theoretic foundation and reference for the development of such substances as clinical drugs.

Key words: Helicobacter pylori, drug resistance, non-antibiotic active substance, nature product, antibacterial activity